OUTCOME AND TOXICITY OF TOTAL NEOADJUVANT THERAPY IN RECTAL CANCER

Recruiting

• Conditions: C20; Malignant neoplasm of rectum

• Registration Number: DRKS00033000
• Lead Sponsor: niversitätsklinikum Jena

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

Patients with locally advanced rectal cancer (LARC), UICC stage II/III who underwent total neoadjuvant therapy (TNT)

adequately measured tumor response (histologically and / or radiologically plus endoscopically)

available follow-up data (min. 6 months)

Exclusion Criteria

Enrollment in other ongoing clinical trials

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
complete remission rate

Secondary Outcome Measures

Name	Time	Method
treatment schedule (i.e. fractionation of radiation, duration of radiation and chemotherapy respectively, chemotherapy dosing, cumulative chemotherapy dose)<br>toxicity during and after therapy<br>quality / results of surgery<br>survival rates (overall, disease-free, colostomy-free), relapse rate<br>quality of life